

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

triheptanoin (Dojolvi)

Initiation (new start) criteria: Non-formulary **triheptanoin (Dojolvi)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a specialist experienced in the treatment of long-chain fatty acid oxidation disorders (LC-FAOD).
- Diagnoses confirmed by molecular genetic testing for one of the following long-chain fatty acid oxidation disorders (LC-FAOD):
 - Very long-chain acylCoA dehydrogenase (VLCAD)
 - Carnitine palmitoyltransferase 2 (CPT2)
 - Mitochondrial trifunctional protein (TFP)
 - Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)
 - Carnitine acylcarnitine translocase (CACT)
- Patient has experienced recurrent rhabdomyolysis or cardiomyopathy that has not improved with reduced dietary intake of long-chain fats plus supplementation with medium chain triglycerides (MCT).
- Patient must have received prior treatment with standard medical therapy for LC-FAOD including MCT supplementation and diet restriction of long-chain fats.

Criteria for new members entering Kaiser Permanente already taking the medication who have not been reviewed previously: Non-formulary **generic (Brand)** will be covered on the prescription drug benefit when the following criteria are met:

- Prescribed by a specialist experienced in the treatment of long-chain fatty acid oxidation disorders (LC-FAOD).
- Diagnoses confirmed by molecular genetic testing for one of the following long-chain fatty acid oxidation disorders (LC-FAOD):
 - Very long-chain acylCoA dehydrogenase (VLCAD)
 - Carnitine palmitoyltransferase 2 (CPT2)
 - Mitochondrial trifunctional protein (TFP)
 - Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD)
 - Carnitine acylcarnitine translocase (CACT)
- Patient has experienced recurrent rhabdomyolysis or cardiomyopathy that has not improved with reduced dietary intake of long-chain fats plus supplementation with medium chain triglycerides (MCT).
- Patient must have received prior treatment with standard medical therapy for LC-FAOD including MCT supplementation and diet restriction of long-chain fats.

kp.org

Revised: 01/14/21
Effective: 03/18/21

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest